• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

MOLECULAR PARTNERS N (MOLN)

Sell: 2.78 CHF|Buy: 3.01 CHF|Change: 0.01 (-0.53%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Find out more

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPintherapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Address




Website

https://www.molecularpartners.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Molecular Partners AG Second Quarter Earnings Results for 20262026-08-25T00:00:00
Molecular Partners AG Second Quarter Earnings Conference Call for 20262026-08-25T00:00:00
Molecular Partners AG Annual General Meeting for 20262026-04-16T09:00:00
Molecular Partners AG Fourth Quarter Earnings Conference Call for 20252026-03-06T08:00:00
Molecular Partners AG Fourth Quarter Earnings Results for 20252026-03-06T00:00:00
Molecular Partners AG Annual Report for 20252026-03-06T00:00:00

Previous key dates

NameKey Date
Molecular Partners AG Second Quarter Earnings Result for 20252025-08-25T00:00:00
Molecular Partners AG Second Quarter Earnings Conference Call for 20252025-08-25T00:00:00
Molecular Partners AG Unknown TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA2025-05-28T10:00:00
H.C. Wainwright 3rd Annual BioConnect Investor Conference2025-05-20T15:30:00
Molecular Partners AG Annual General Meeting for 20252025-04-16T09:00:00
Leerink Partners Global Healthcare Conference 20252025-03-10T10:40:00
Molecular Partners AG Fourth Quarter Earnings Conference Call for 20242025-03-07T08:00:00
Molecular Partners AG Fourth Quarter Earnings Result for 20242025-03-07T00:00:00
Molecular Partners AG Annual Report for 20242025-03-06T00:00:00
TD Cowen 44th Annual Health Care Conference2025-03-03T09:10:00
43rd Annual JP Morgan Healthcare Conference2025-01-15T09:00:00
Baader Helvea Swiss Equities Conference2025-01-08T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.